Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 25, 2026, 9:28 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Skin Cancer Prevention Clear all
Completed Not applicable Interventional Accepts healthy volunteers

DAMES: Daughters And MothErS Against Breast Cancer

NCT00630591
View directory record Official record
Conditions
Breast Cancer
Interventions
Standardized Materials Group, Independent Tailored Intervention, Partner-Assisted Tailored Intervention
Behavioral
Lead sponsor
Duke University
Other
Eligibility
21 Years and older · Female only
Enrollment
482 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
2
States / cities
Durham, North Carolina • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 1, 2017 · Synced Jun 25, 2026, 9:28 PM EDT
Recruiting Phase 2 Interventional

HERizon-Breast: A ctDNA-Guided Adaptive Study of Sequential Anti-HER2 Therapies and CNS Prophylaxis to Induce Long-Term Remission

NCT07459673
View directory record Official record
Conditions
Breast Cancer, HER2-positive Breast Cancer, Breast Cancer Stage IV
Interventions
Personalis NeXT Personal, Natera Signatera, fam-trastuzumab deruxtecan-nxki (T-DXd), pertuzumab, called T-DXd+P
Diagnostic Test · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Jun 25, 2026, 9:28 PM EDT
Completed Not applicable Interventional Results available

Warning Signs of Squamous Cell Carcinoma and Prevention of SCC by at Risk Organ Transplant Recipients

NCT01127737
View directory record Official record
Conditions
Squamous Cell Carcinoma
Interventions
Educational Intervention, Placebo
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 85 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 2, 2015 · Synced Jun 25, 2026, 9:28 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

T-DM1 Alone Versus T-DM1 and Metronomic Temozolomide in Secondary Prevention of HER2-Positive Breast Cancer Brain Metastases Following Stereotactic Radiosurgery

NCT03190967
View directory record Official record
Conditions
Breast Cancer, Brain Metastasis, Brain Cancer
Interventions
T-DM1, TMZ
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 10, 2023 · Synced Jun 25, 2026, 9:28 PM EDT
Completed Phase 1 Interventional

Fingolimod in Preventing Paclitaxel-Associated Neuropathy in Patients With Breast Cancer

NCT03941743
View directory record Official record
Conditions
Breast Carcinoma
Interventions
Fingolimod, Fingolimod Hydrochloride, Questionnaire Administration
Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
3
States / cities
Rochester, Minnesota • Columbus, Ohio • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 20, 2023 · Synced Jun 25, 2026, 9:28 PM EDT
Terminated Phase 1 Interventional

A Study of ALRN-6924 for Protection of Chemotherapy-Induced Side Effects in Patients With TP53-Mutant Breast Cancer

NCT05622058
View directory record Official record
Conditions
Prevention of Chemotherapy-induced Myelosuppression
Interventions
ALRN-6924, TAC (doxorubicin 50 mg/m2; cyclophosphamide 500 mg/m2; docetaxel 75 mg/m2)
Drug
Lead sponsor
Aileron Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
5
States / cities
Tamarac, Florida • Huntersville, North Carolina • Wilson, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2023 · Synced Jun 25, 2026, 9:28 PM EDT
Terminated No phase listed Observational Results available

Breath Test for Women Receiving Tamoxifen in the Prevention or Treatment of Breast Cancer

NCT00873366
View directory record Official record
Conditions
Breast Cancer
Interventions
dextromethorphan hydrobromide, tamoxifen citrate, high performance liquid chromatography, laboratory biomarker analysis, pharmacogenomic studies, pharmacological study, fluorescence imaging
Drug · Other · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 120 Years · Female only
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
2
States / cities
Scottsdale, Arizona • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 22, 2018 · Synced Jun 25, 2026, 9:28 PM EDT
Completed Phase 3 Interventional

S9630, Medroxyprogesterone in Treating Women With Breast Cancer

NCT00002920
View directory record Official record
Conditions
Breast Cancer, Endometrial Cancer
Interventions
medroxyprogesterone, tamoxifen citrate, adjuvant therapy
Drug · Procedure
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older · Female only
Enrollment
313 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2009
U.S. locations
122
States / cities
Mobile, Alabama • Anchorage, Alaska • Phoenix, Arizona + 84 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2012 · Synced Jun 25, 2026, 9:28 PM EDT
Completed Phase 3 Interventional Results available

Mometasone Furoate in Preventing Radiation Dermatitis in Patients Undergoing Radiation Therapy to the Breast or Chest Wall for Invasive Breast Cancer or Ductal Carcinoma in Situ

NCT00438659
View directory record Official record
Conditions
Breast Cancer, Dermatologic Complications, Radiation Toxicity, Skin Reactions Secondary to Radiation Therapy
Interventions
mometasone furoate, placebo
Drug · Other
Lead sponsor
North Central Cancer Treatment Group
Network
Eligibility
18 Years and older
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
189
States / cities
Aurora, Illinois • Bloomington, Illinois • Canton, Illinois + 116 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2016 · Synced Jun 25, 2026, 9:28 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Rural Adult and Youth Sun Protection Study

NCT06439979
View directory record Official record
Conditions
Melanoma (Skin), Skin Cancer
Interventions
RAYS Intervention
Behavioral
Lead sponsor
University of Utah
Other
Eligibility
3 Years to 7 Years
Enrollment
843 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2030
U.S. locations
2
States / cities
Salt Lake City, Utah • Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Jun 25, 2026, 9:28 PM EDT
Suspended Phase 2Phase 3 Interventional

Hypofractionated Partial Breast Irradiation in Treating Patients With Early Stage Breast Cancer

NCT03077841
View directory record Official record
Conditions
Ductal Breast Carcinoma In Situ, Early-Stage Breast Carcinoma, Invasive Breast Carcinoma, Stage 0 Breast Cancer AJCC v6 and v7, Stage I Breast Cancer AJCC v7, Stage IA Breast Cancer AJCC v7, Stage IB Breast Cancer AJCC v7, Stage II Breast Cancer AJCC v6 and v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7
Interventions
Laboratory Biomarker Analysis, Partial Breast Irradiation, Questionnaire Administration
Other · Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
50 Years and older · Female only
Enrollment
928 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
15
States / cities
Jacksonville, Florida • Atlanta, Georgia • Indianapolis, Indiana + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Jun 25, 2026, 9:28 PM EDT
Not yet recruiting No phase listed Observational Accepts healthy volunteers

The RISC Registry--Risk Informed Screening Registry

NCT05848856
View directory record Official record
Conditions
Breast Cancer Risk, Cardiovascular Disease Risk, Cardiometabolic Risk, Diabetes
Interventions
Breast Cancer, Cardiometabolic, Cardiovascular Risk Screening and Follow up
Behavioral
Lead sponsor
Precision Health Equity Initiative
Other
Eligibility
18 Years to 100 Years · Female only
Enrollment
10,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2035
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jul 10, 2024 · Synced Jun 25, 2026, 9:28 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Virtual Sun Safe Workplaces Ph I

NCT05146622
View directory record Official record
Conditions
Skin Cancer
Interventions
Workplaces in the World
Behavioral
Lead sponsor
Klein Buendel, Inc.
Industry
Eligibility
18 Years and older
Enrollment
104 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Golden, Colorado
Source: ClinicalTrials.gov public record
Updated Nov 3, 2022 · Synced Jun 25, 2026, 9:28 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

CATCH-UP Intervention in Increasing Cancer Screening and Prevention Care in Uninsured Patients at Community Health Centers

NCT02355262
View directory record Official record
Conditions
Breast Carcinoma, Cervical Carcinoma, Colorectal Carcinoma, Health Status Unknown, Human Papillomavirus Infection, Malignant Neoplasm
Interventions
Informational Intervention
Other
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2020
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 18, 2020 · Synced Jun 25, 2026, 9:28 PM EDT
Completed Phase 3 Interventional

Itraconazole Compared With Fluconazole to Prevent Infections in Patients Undergoing Peripheral Stem Cell or Bone Marrow Transplantation

NCT00003883
View directory record Official record
Conditions
Cancer
Interventions
fluconazole, itraconazole
Drug
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
13 Years and older
Enrollment
578 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2002
U.S. locations
2
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 1, 2010 · Synced Jun 25, 2026, 9:28 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Sun Safety Skills for Elementary School Students

NCT03752736
View directory record Official record
Conditions
Sunburn, Skin Cancer Prevention
Interventions
"I wear sunscreen everyday" song-based video
Behavioral
Lead sponsor
Stanford University
Other
Eligibility
5 Years to 7 Years
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Cupertino, California
Source: ClinicalTrials.gov public record
Updated Aug 12, 2019 · Synced Jun 25, 2026, 9:28 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Using Technology to Scale-Up an Occupational Sun Protection Policy Program

NCT03278340
View directory record Official record
Conditions
Skin Cancer
Interventions
Sun Safe Workplaces - Technology, Sun Safe Workplaces -In Person
Behavioral
Lead sponsor
Klein Buendel, Inc.
Industry
Eligibility
18 Years and older
Enrollment
2,644 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2024
U.S. locations
2
States / cities
Oakland, California • Golden, Colorado
Source: ClinicalTrials.gov public record
Updated Nov 13, 2024 · Synced Jun 25, 2026, 9:28 PM EDT
Completed Phase 3 Interventional Results available

Prevention of Delayed Nausea A Phase III Double-Blind Placebo-Controlled Clinical Trial

NCT00475085
View directory record Official record
Conditions
Nausea
Interventions
aprepitant, dexamethasone, granisetron hydrochloride, palonosetron hydrochloride, prochlorperazine, placebo
Drug
Lead sponsor
Joseph Roscoe
Other
Eligibility
18 Years and older
Enrollment
1,021 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
16
States / cities
Mobile, Alabama • Decatur, Illinois • Wichita, Kansas + 13 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2015 · Synced Jun 25, 2026, 9:28 PM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers

Education for Prevention of Melanoma in Hispanic Populations

NCT05388851
View directory record Official record
Conditions
Melanoma
Interventions
Educational Intervention, Questionnaire Administration
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
145 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 21, 2025 · Synced Jun 25, 2026, 9:28 PM EDT
Terminated Phase 2 Interventional Results available

Topical Tazarotene Vs Placebo In Hand-Foot-Skin Reactions

NCT04071756
View directory record Official record
Conditions
Solid Tumor, Hand-Foot Skin Reaction (HFSR)
Interventions
Topical Tazarotene, Placebo
Drug · Other
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 6, 2024 · Synced Jun 25, 2026, 9:28 PM EDT
Completed Not applicable Interventional

Pilot Study of Curcumin for Women With Obesity and High Risk for Breast Cancer

NCT01975363
View directory record Official record
Conditions
Atypical Ductal Breast Hyperplasia, BRCA1 Gene Mutation, BRCA2 Gene Mutation, Ductal Breast Carcinoma in Situ, Lobular Breast Carcinoma in Situ
Interventions
curcumin, Biomarker analysis, Assessment of Dietary Intake, Daily Log
Dietary Supplement · Other
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
19 Years and older · Female only
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 29, 2019 · Synced Jun 25, 2026, 9:28 PM EDT
Completed Not applicable Interventional Results available

Family Lifestyle Actions and Risk Education Study

NCT02846714
View directory record Official record
Conditions
Melanoma, Child
Interventions
FLARE
Behavioral
Lead sponsor
University of Utah
Other
Eligibility
8 Years to 110 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated May 7, 2019 · Synced Jun 25, 2026, 9:28 PM EDT
Completed Phase 3 Interventional

Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer in Postmenopausal Women

NCT00003906
View directory record Official record
Conditions
Breast Cancer
Interventions
Raloxifene, Tamoxifen
Drug
Lead sponsor
NSABP Foundation Inc
Network
Eligibility
35 Years and older · Female only
Enrollment
19,747 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2012
U.S. locations
492
States / cities
Huntsville, Alabama • Mobile, Alabama • Anchorage, Alaska + 369 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2015 · Synced Jun 25, 2026, 9:28 PM EDT
Recruiting No phase listed Observational

Impact of Dietary Inflammatory Potential on Breast Cancer Risk

NCT05178498
View directory record Official record
Conditions
Breast Atypical Ductal Hyperplasia, Breast Atypical Lobular Hyperplasia, Breast Carcinoma, Breast Lobular Carcinoma In Situ, Breast Sclerosing Adenosis
Interventions
Follow-Up, Physical Examination, Questionnaire Administration
Procedure · Other
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
960 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2035
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Jun 25, 2026, 9:28 PM EDT